PT - JOURNAL ARTICLE AU - HIROFUMI SUZUMURA AU - MASASHI TSURUTA AU - KOJI OKABAYASHI AU - KOHEI SHIGETA AU - RYO SEISHIMA AU - TAKASHI ISHIDA AU - TAKEHIRO SHIMADA AU - YUSUKE ASADA AU - KAORU KOISHIKAWA AU - SHINGO AKIMOTO AU - OSAMU ITANO AU - HIROTOSHI HASEGAWA AU - YUKO KITAGAWA TI - BAF57 Is a Potential Determinant of Colorectal Cancer Malignancy AID - 10.21873/anticanres.15356 DP - 2021 Nov 01 TA - Anticancer Research PG - 5445--5452 VI - 41 IP - 11 4099 - http://ar.iiarjournals.org/content/41/11/5445.short 4100 - http://ar.iiarjournals.org/content/41/11/5445.full SO - Anticancer Res2021 Nov 01; 41 AB - Background/Aim: The role of brahma-related gene 1 (BRG1)-associated factor 57 (BAF57), a transcription factor, has been determined in prostate, breast, and ovarian cancer. However, the relationship between BAF57 and colorectal cancer (CRC) is obscure. Thus, we examined the functional correlation between BAF57 expression and oncological malignancy in CRC in vitro. Materials and Methods: BAF57 expression in WiDr and HT29 CRC cell lines and clinical specimens from CRC patients was analysed by western blotting and/or RT-PCR. BAF57 expression was down-regulated in WiDr cells through siRNA transfection. An invasion assay was also performed to assess malignancy. Results: BAF57 was expressed in both human CRC cell lines. Overall survival and recurrence-free survival rates were significantly reduced in high BAF57-expressing specimens. BAF57 expression was an independent predictive factor for long-term survival. Conclusion: BAF57 correlates with oncological malignancy and may be a novel therapeutic target in CRC.